Atp Life Science Ventures, L.p. - Net Worth and Insider Trading

Atp Life Science Ventures, L.p. Net Worth

The estimated net worth of Atp Life Science Ventures, L.p. is at least $423 Million dollars as of 2024-11-13. Atp Life Science Ventures, L.p. is the 10% Owner of Stoke Therapeutics Inc and owns about 17,161,713 shares of Stoke Therapeutics Inc (STOK) stock worth over $234 Million. Atp Life Science Ventures, L.p. is also the 10% Owner of Akero Therapeutics Inc and owns about 5,830,203 shares of Akero Therapeutics Inc (AKRO) stock worth over $189 Million. Details can be seen in Atp Life Science Ventures, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Atp Life Science Ventures, L.p. has not made any transactions after 2020-11-24 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Atp Life Science Ventures, L.p.

To

Atp Life Science Ventures, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Atp Life Science Ventures, L.p. owns 5 companies in total, including Akero Therapeutics Inc (AKRO) , Stoke Therapeutics Inc (STOK) , and Avalo Therapeutics Inc (AVTX) among others .

Click here to see the complete history of Atp Life Science Ventures, L.p.’s form 4 insider trades.

Insider Ownership Summary of Atp Life Science Ventures, L.p.

Ticker Comapny Transaction Date Type of Owner
AKRO Akero Therapeutics Inc 2021-06-28 10 percent owner
STOK Stoke Therapeutics Inc 2021-06-28 10 percent owner
AVTX Avalo Therapeutics Inc 2015-10-14 director & 10 percent owner
LIMIT LIMIT 2014-09-22 director & 10 percent owner
LIMIT LIMIT 2013-11-25 10 percent owner

Atp Life Science Ventures, L.p. Latest Holdings Summary

Atp Life Science Ventures, L.p. currently owns a total of 2 stocks. Among these stocks, Atp Life Science Ventures, L.p. owns 17,161,713 shares of Stoke Therapeutics Inc (STOK) as of November 24, 2020, with a value of $234 Million and a weighting of 55.32%. Atp Life Science Ventures, L.p. also owns 5,830,203 shares of Akero Therapeutics Inc (AKRO) as of July 10, 2020, with a value of $189 Million and a weighting of 44.68%.

Latest Holdings of Atp Life Science Ventures, L.p.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
STOK Stoke Therapeutics Inc 2020-11-24 17,161,713 13.62 233,742,531
AKRO Akero Therapeutics Inc 2020-07-10 5,830,203 32.38 188,781,973

Holding Weightings of Atp Life Science Ventures, L.p.


Atp Life Science Ventures, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Atp Life Science Ventures, L.p. has made a total of 1 transactions in Stoke Therapeutics Inc (STOK) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Stoke Therapeutics Inc is the acquisition of 375,000 shares on November 24, 2020, which cost Atp Life Science Ventures, L.p. around $15 Million.

According to the SEC Form 4 filings, Atp Life Science Ventures, L.p. has made a total of 1 transactions in Akero Therapeutics Inc (AKRO) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Akero Therapeutics Inc is the acquisition of 415,000 shares on July 10, 2020, which cost Atp Life Science Ventures, L.p. around $15 Million.

Insider Trading History of Atp Life Science Ventures, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Atp Life Science Ventures, L.p. Trading Performance

GuruFocus tracks the stock performance after each of Atp Life Science Ventures, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Atp Life Science Ventures, L.p. is -1.56%. GuruFocus also compares Atp Life Science Ventures, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Atp Life Science Ventures, L.p. within 3 months outperforms 2 times out of 4 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Atp Life Science Ventures, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Atp Life Science Ventures, L.p.

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 4 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 5.62 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 2.93 LIMIT LIMIT LIMIT LIMIT LIMIT

Atp Life Science Ventures, L.p. Ownership Network

Ownership Network List of Atp Life Science Ventures, L.p.

No Data

Ownership Network Relation of Atp Life Science Ventures, L.p.

Insider Network Chart

Atp Life Science Ventures, L.p. Owned Company Details

What does Akero Therapeutics Inc do?

Who are the key executives at Akero Therapeutics Inc?

Atp Life Science Ventures, L.p. is the 10 percent owner of Akero Therapeutics Inc. Other key executives at Akero Therapeutics Inc include Chief Development Officer Catriona Yale , director & President & CEO Andrew Cheng , and Chief Operating Officer Jonathan Young .

Akero Therapeutics Inc (AKRO) Insider Trades Summary

Over the past 18 months, Atp Life Science Ventures, L.p. made no insider transaction in Akero Therapeutics Inc (AKRO). Other recent insider transactions involving Akero Therapeutics Inc (AKRO) include a net sale of 171,998 shares made by Jonathan Young , a net sale of 150,584 shares made by Catriona Yale , and a net sale of 443,502 shares made by Andrew Cheng .

In summary, during the past 3 months, insiders sold 488,023 shares of Akero Therapeutics Inc (AKRO) in total and bought 0 shares, with a net sale of 488,023 shares. During the past 18 months, 1,237,763 shares of Akero Therapeutics Inc (AKRO) were sold and 1,320,000 shares were bought by its insiders, resulting in a net purchase of 82,237 shares.

Akero Therapeutics Inc (AKRO)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Akero Therapeutics Inc Insider Transactions

No Available Data

Atp Life Science Ventures, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Atp Life Science Ventures, L.p.. You might contact Atp Life Science Ventures, L.p. via mailing address: 230 Park Avenue, Suite 2800, New York Ny 10169.